

Special Issue

Progress in Targeted Nanotherapeutic Delivery Systems for Cancer Precision Medicine

Message from the Guest Editors

Cancer remains one of the leading causes of death globally, compelling substantial investments in understanding tumor mechanisms and urging advancements in precision medicine. While newer inhibitors, RNAi drugs, and immunotherapy targets have provided strategic therapeutic solutions, effective transport of therapeutic molecules to the intended tumor site remains a major challenge in precision cancer therapy. Therefore, there is a clinical need to develop and explore innovative solutions to cancer drug delivery.

Pioneering initiatives to overcome the challenge have involved the use of healthcare-related nanomaterials. Importantly, this issue will rigorously focus on the synthesis rationale, nanomedicine's biocompatibility, scalability, and reproducibility, efficiency in selective targeting and drug delivery, tumor penetration (in 3D tumoroids and animals), and therapeutic efficacy.

We invite investigators to contribute their original research articles or reviews that provide new insights into nanomaterial phenomena, synthesis, and its translation towards effective cancer drug delivery and personalized cancer therapy.

Guest Editors

Dr. Linlin Zhang

Department of Bioengineering, Rice University, Houston, TX, USA

Dr. Dhananjay Suresh

School of Medicine, University of Missouri, Columbia, MO, USA

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/254109

Cancers

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

cancers@mdpi.com

mdpi.com/journal/

[cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)